Filing Flows › Comparisons › PLX vs RXRX
Protalix BioTherapeutics vs Recursion Pharmaceuticals: PLX and RXRX compared
Protalix BioTherapeutics is the larger company: $19.9M of revenue in its latest quarter (Q2 2026) against $18.6M for Recursion Pharmaceuticals (Q3 2026). Recursion Pharmaceuticals is growing faster (+258% against +27% a year earlier). Protalix BioTherapeutics is more profitable, with an operating margin of 23.5% against -663.9%.
Where the money goes: PLX and RXRX
Protalix BioTherapeutics (PLX) · Q2 2026
Protalix BioTherapeutics, Q2 2026: revenue $19.9M (+27% year over year), operating margin 23.5%, net earnings $3.8M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
Recursion Pharmaceuticals (RXRX) · Q3 2026
Recursion Pharmaceuticals, Q3 2026: revenue $18.6M (+258% year over year), operating margin -663.9%, net loss $119M, operating cash flow −$77.4M. The chart follows the revenue to costs, profit and cash.
| Protalix BioTherapeutics (PLX) | Recursion Pharmaceuticals (RXRX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $19.9M | $18.6M |
| Revenue growth, Y/Y | +27% | +258% |
| Operating margin | 23.5% | -663.9% |
| Net earnings | $3.8M | −$119M |
| Net margin | 19.0% | -641.6% |
| Operating cash flow | −$10.4M | −$77.4M |
Where the revenue comes from
Protalix BioTherapeutics
- GOODS: $19.8M (100%)
- LICENSE AND R&D SERVICES: $68K (0%)
Recursion Pharmaceuticals
- Operating revenue: $18.1M (97%)
- Grant revenue: $497K (3%)
Questions
Which is bigger, Protalix BioTherapeutics or Recursion Pharmaceuticals?
Protalix BioTherapeutics is the larger company: $19.9M of revenue in its latest quarter (Q2 2026) against $18.6M for Recursion Pharmaceuticals (Q3 2026).
Is Protalix BioTherapeutics or Recursion Pharmaceuticals growing faster?
Recursion Pharmaceuticals is growing faster (+258% against +27% a year earlier).
Which is more profitable, Protalix BioTherapeutics or Recursion Pharmaceuticals?
Protalix BioTherapeutics is more profitable, with an operating margin of 23.5% against -663.9%.
More: Protalix BioTherapeutics earnings · how Protalix BioTherapeutics makes money · Recursion Pharmaceuticals earnings · how Recursion Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Nov 2, 2026). Fiscal quarters can end on different dates. Not investment advice.